Patient with non-alcoholic fatty liver disease at care encounter of a therapist: Aspects of diagnostics and treatment

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease of metabolic origin in individuals without exogenous factors of toxic damage. It is associated not only with an unfavorable hepatic prognosis, but also with cardiovascular morbidity and mortality increase. There is existing a bidirectional relationship between NAFLD and type 2 diabetes mellitus; in addition, there is close comorbidity between NAFLD and a number of other pathologies. Currently, this hepatic disease is becoming the same non-infectious epidemic as cancer, obesity, diabetes mellitus, cardiovascular diseases, and a multidisciplinary approach to its treatment includes the improvement of not only «liver health» parameters, but also the health of the patient as a whole. Article discusses the key areas of examination and treatment of a patient with a presumed diagnosis of NAFLD.

Full Text

Restricted Access

About the authors

Svetlana V. Turkina

Volgograd State Medical University of the Ministry of Healthcare of Russia

Author for correspondence.
Email: turkina.vlg@gmail.com
ORCID iD: 0000-0002-8844-2465

MD, Professor of the Department of Internal Diseases

Russian Federation, Volgograd

Mikhail E. Statsenko

Volgograd State Medical University of the Ministry of Healthcare of Russia

Email: mestatsenko@rambler.ru
ORCID iD: 0000-0002-3306-0312

MD, Professor, Vice Rector for Research, Head of the Department of Internal Diseases

Russian Federation, Volgograd

Marina A. Kosivtsova

Volgograd State Medical University of the Ministry of Healthcare of Russia

Email: marinalekcandrovna@yandex.ru
ORCID iD: 0000-0002-4718-5028

PhD in Medical Sciences, Associate Professor of the Department of Internal Diseases

Russian Federation, Volgograd

Marina N. Titarenko

Volgograd State Medical University of the Ministry of Healthcare of Russia

Email: manina26@mail.ru
ORCID iD: 0000-0002-3749-6076

PhD in Medical Sciences, Associate Professor of the Department of Internal Diseases

Russian Federation, Volgograd

Irina A. Tyshchenko

Volgograd State Medical University of the Ministry of Healthcare of Russia

Email: tishenco-card@rambler.ru
ORCID iD: 0000-0002-3046-7264

PhD in Medical Sciences, Associate Professor of the Department of Internal Diseases

Russian Federation, Volgograd

References

  1. Лазебник Л.Б., Голованова Е.В., Туркина С.В. с соавт. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021; 185(1): 4–52. [Lazebnik L.B., Golovanova E.V., Turkina S.V. et al. Non-alcoholic fatty liver disease in adults: Clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2021; 185(1): 4–52 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-185-1-4-52. EDN: KJLOJV.
  2. Le M.H., Yeo Y.H., Li X. et al. 2019 global NAFLD prevalence: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022; 20(12): 2809–17.e28. https://dx.doi.org/10.1016/j.cgh.2021.12.002.
  3. Riazi K., Azhari H., Charette J.H. et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7(9): 851–61. https://dx.doi.org/10.1016/S2468-1253(22)00165-0.
  4. Simon T.G., Roelstraete B., Khalili H. et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: Results from a nationwide cohort. Gut. 2021; 70(7): 1375–82. https://dx.doi.org/10.1136/gutjnl-2020-322786.
  5. Kasper P., Martin A., Lang S. et al. NAFLD and cardiovascular diseases: A clinical review. Clin Res Cardiol. 2021; 110(7): 921–37. https://dx.doi.org/10.1007/s00392-020-01709-7.
  6. Stefan N., Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022; 10(4): 284–96. https://dx.doi.org/10.1016/S2213-8587(22)00003-1.
  7. Padda J., Khalid K., Khedr A. et al. Non-alcoholic fatty liver disease and its association with diabetes mellitus. Cureus. 2021; 13(8): e17321. https://dx.doi.org/10.7759/cureus.17321.
  8. Wang Z., Zhao X., Chen S. et al. Associations between nonalcoholic fatty liver disease and cancers in a large cohort in China. Clin Gastroenterol Hepatol. 2021; 19(4): 788–96.e4. https://dx.doi.org/10.1016/j.cgh.2020.05.009.
  9. Riazi K., Azhari H., Charette J.H. et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7(9): 851–61. https://dx.doi.org/10.1016/S2468-1253(22)00165-0.
  10. Li J., Zou B, Yeo Y.H. et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019; 4(5): 389–98. https://dx.doi.org/10.1016/S2468-1253(19)30039-1.
  11. Ивашкин В.Т., Драпкина О.М., Маев И.В. с соавт. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015; 25(6): 31–41. [Ivashkin V.T., Drapkina O.M., Mayev I.V. et al. Prevalence of non-alcoholic fatty liver disease in outpatients of the Russian Federation: DIREG 2 study results. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015; 25(6): 31–41 (In Russ.)]. EDN: VOXFQP.
  12. Евстифеева С.Е., Шальнова С.А., Куценко В.А. с соавт. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022; 21(9): 40–49. [Evstifeeva S.E., Shalnova S.A., Kutsenko V.A. et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2022; 21(9): 40–49 (In Russ.)]. https://dx.doi.org/10.15829/1728-8800-2022-3356. EDN: SITSBL.
  13. Ye Q., Zou B., Yeo Y.H. et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5(8): 739–52. https://dx.doi.org/10.1016/S2468-1253(20)30077-7.
  14. Moolla A., Motohashi K., Marjot T. et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol. 2019; 10(4): 337–46. https://dx.doi.org/10.1136/flgastro-2018-101155.
  15. Ruissen M.M., Mak A.L., Beuers U. et al. Non-alcoholic fatty liver disease: A multidisciplinary approach towards a cardiometabolic liver disease. Eur J Endocrinol. 2020; 183(3): R57–R73. https://dx.doi.org/10.1530/EJE-20-0065.
  16. Francque S.M., Marchesini G., Kautz A. et al. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep. 2021; 3(5): 100322. https://dx.doi.org/10.1016/j.jhepr.2021.100322.
  17. Lazarus J.V., Mark H.E., Anstee Q.M. et al.; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: A consensus statement. Nat Rev Gastroenterol Hepatol. 2022; 19(1): 60–78. https://dx.doi.org/10.1038/s41575-021-00523-4.
  18. Schattenberg J.M., Allen A.M., Jarvis H. et al. A multistakeholder approach to innovations in NAFLD care. Commun Med (Lond). 2023; 3(1): 1. https://dx.doi.org/10.1038/s43856-022-00228-y.
  19. Ajmera V., Cepin S., Tesfai K. et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023; 78(3): 471–78. https://dx.doi.org/10.1016/j.jhep.2022.11.010.
  20. Лазебник Л.Б., Голованова Е.В., Хлынова О.В. с соавт. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020; 174(2): 29–54. [Lazebnik L.B., Golovanova E.V., Hlynova О.V. et al. Medicinal liver damage in adults. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2020; 174(2): 29–54 (In Russ.)]. https://dx.doi.org/1010.31146/1682-8658-ecg-174-2-29-54. EDN: RNLXSH.
  21. Лазебник Л.Б., Голованова Е.В., Еремина Е.Ю. с соавт. Алкогольная болезнь печени (АБП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020; 174(2): 4–28. [Lazebnik L.B., Golovanova E.V., Tarasova L.V. et al. Adult alcoholic liver disease. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2020; 174(2): 4–28 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-174-2-4-28. EDN: XTGVGB.
  22. Eslam M., Newsome P.N., Sarin S.K. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1): 202–9. https://dx.doi.org/10.1016/j.jhep.2020.03.039.
  23. Gehrke N., Schattenberg J.M. Metabolic inflammation-a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease? Gastroenterology. 2020; 158(7): 1929–47.e6. https://dx.doi.org/10.1053/j.gastro.2020.02.020.
  24. Еuropean Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6): 1388–402. https://dx.doi.org/10.1016/j.jhep.2015.11.004.
  25. Chalasani N., Younossi Z., Lavine J.E. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67(1): 328–57. https://dx.doi.org/10.1002/hep.29367.
  26. Dinani A., Sussman N., Noureddin M. et al. An algorithm for the management of non-alcoholic fatty liver disease in primary care. Gastroenterol Hepatol Open Access. 2021; 12(4): 114-22. https://dx.doi.org/10.15406/ghoa.2021.12.00469.
  27. Angulo P., Hui J.M., Marchesini G. et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45(4): 846–54. https://dx.doi.org/10.1002/hep.21496.
  28. McPherson S., Stewart S.F., Henderson E. et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010; 59(9): 1265–69. https://dx.doi.org/10.1136/gut.2010.216077.
  29. Loomba R. Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions. J Hepatol. 2018; 68(2): 296–304. https://dx.doi.org/10.1016/j.jhep.2017.11.028.
  30. Stahl E.P., Dhindsa D.S., Lee S.K. et al. Nonalcoholic fatty liver disease and the heart: JACC State-of-the-art review. J Am Coll Cardiol. 2019; 73(8): 948–63. https://dx.doi.org/10.1016/j.jacc.2018.11.050.
  31. Duell P.B., Welty F.K., Miller M. et al.; ; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022; 42(6): e168–85. https://dx.doi.org/10.1161/ATV.0000000000000153.
  32. Kweon Y.N., Ko H.J., Kim A.S. et al Prediction of cardiovascular risk using Nonalcoholic Fatty Liver Disease Scoring Systems. Healthcare. 2021; 9(7):899. https://dx.doi.org/10.3390/healthcare9070899.
  33. Bedogni G., Bellentani S., Miglioli L. et al. The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6: 33. https://dx.doi.org/10.1186/1471-230X-6-33.
  34. Kunutsor S.K., Bakker S.JL., Blokzijl H. et al. Associations of the fatty liver and hepatic steatosis indices with risk of cardiovascular disease: Interrelationship with age. Clin Chim Acta. 2017; 466: 54–60. https://dx.doi.org/10.1016/j.cca.2017.01.008.
  35. MD+ CALC. Fatty Liver Index. URL: https://www.mdcalc.com/fatty-liver-index (date of access – 01.11.2023).
  36. URL: https://nafldscore.com/ (date of access – 01.11.2023).
  37. Hepatitis C online. Fibrosis-4 (FIB-4) calculator. URL: https://www.hepatitisc.uw.edu/page/clinical-calculators/fib-4 (date of access – 01.11.2023).
  38. Medsoftpro. Шкала SCORE2, SCORE2-OP. Онлайн калькулятор. Доступ: https://medsoftpro.ru/kalkulyatory/score2-scale.html (дата обращения – 01.11.2023). [Medsoftpro. SCORE2, SCORE2-OP scale. Online calculator. URL: https://medsoftpro.ru/kalkulyatory/score2-scale.html (date of access – 01.11.2023) (In Russ.)].
  39. Karam G., Agarwal A., Sadeghirad B. et al. Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: Systematic review and network meta-analysis. BMJ. 2023; 380: e072003. https://dx.doi.org/10.1136/bmj-2022-072003.
  40. Cigrovski Berkovic M., Bilic-Curcic I., Mrzljak A., Cigrovski V. NAFLD and physical exercise: Ready, steady, go! Front Nutr. 2021; 8: 734859. https://dx.doi.org/10.3389/fnut.2021.734859.
  41. Keating S.E., Hackett D.A., Parker H.M. et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity. J Hepatol. 2015; 63(1): 174–82. https://dx.doi.org/10.1016/j.jhep.2015.02.022.
  42. Eckard C., Cole R., Lockwood J. et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: A randomized trial. Therap Adv Gastroenterol. 2013; 6(4): 249–59. https://dx.doi.org/10.1177/1756283X13484078.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig 1. NAFLD-associated comorbidity [16]

Download (288KB)
Indexing metadata
3. Fig. 2. Diagnostic criteria of metabolically associated fatty liver disease [22]

Download (236KB)
Indexing metadata
4. Fig. 3. Metabolic inflammation as a basis for the formation of associated pathology in nonalcoholic fatty liver disease [23]

Download (889KB)
Indexing metadata
5. Fig. 4. Nomination and functional classification of hepatoprotectors [1]

Download (199KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies